Thousands of Regulatory Professionals targeted for this global benchmark in Pharmaceutical regulatory trends
Philadelphia, Pennsylvania, USA -- June 13th, 2005 -- Thomson Scientific & Healthcare, the global leader in providing regulatory software solutions, information products and related services for the life sciences industry, today unveiled the early findings of its 2005 Liquent Regulatory Affairs Trends Survey. This annual survey, which is now in its third year, provides insights and perspective into how regulatory departments use technology and how they plan to harness technology in the future. Thousands of regulatory professionals were targeted to gather input for what is today recognized as the premier benchmark of global regulatory submissions trends. Thomson Scientific & Healthcare is part of The Thomson Corporation (NYSE: TOC; TSX: TOC).
Regulatory Affairs departments ensure the appropriate licensing, marketing & legal compliance of pharmaceutical and medical products and have become of pivotal significance to the successful development and bringing to market of new products. The 2005 survey yielded responses from Europe and North America with over half its respondents from the US and the majority of the remaining from Europe, specifically the UK, France and Germany. The 117 respondents represent large, medium and small pharmaceutical companies and a third of respondents came from medical devices and biotechnology companies. The study concentrates on four key areas; Technology Usage Trends, including both submission publishing software and other desktop software, Document Management System usage, Regulatory Outsourcing trends, and Regulatory trends including use or future use of the electronic Common Technical Document (eCTD). This year's survey also addressed the broader regulatory product management needs including registration management, submission project management and product information management both today and in the future.
Survey highlights include:
Jim Nichols is Liquent's Vice President of Product Strategy and Marketing and spearheaded this worldwide initiative, "We are delighted with the response that we have received from pharmaceutical, biotechnology and medical devices companies who have taken the time to respond to our survey and provide such valuable insight into how their regulatory departments use, and plan to use, technology. We also welcome the extensive interest that we have received from publishers and conference organisers and we look forward to releasing the full results in the next few days."
For more information on the survey, its findings and how to secure a copy, please contact info@liquent.com.
About Liquent regulatory solutions
Liquent regulatory solutions provides software, information products, and related services for the life sciences industry. These solutions and services help ensure clients meet the strict standards of regulatory authorities across the world helping them achieve quality, accuracy, and data integrity to deliver regulatory reports and submissions reliably and on time. In addition to technology and services, the Liquent IDRAC database service provides the most comprehensive intelligence on the drug and biologics regulatory environment in 38 of the largest markets in the world.
As a result, 48 of the top 50 global life sciences companies rely on Liquent regulatory solutions to stay current with the latest intelligence and to provide the technology and services to compress the regulatory submissions and approval process, improving speed to market, cost control, and productivity, all of which contribute to ensuring patients' and physicians' timely access to new drugs. Over the last decade, more than 5,000 regulatory submissions have been produced using Liquent world-class products and expert services. For more information please visit, www.liquent.com.
About The Thomson Corporation
The Thomson Corporation (www.thomson.com), with 2004 revenues of $8.10 billion, is a global leader in providing integrated information solutions to business and professional customers. Thomson provides value-added information, software tools and applications to more than 20 million users in the fields of law, tax, accounting, financial services, higher education, reference information, corporate e-learning and assessment, scientific research and healthcare. With operational headquarters in Stamford, Conn., Thomson has approximately 40,000 employees and provides services in approximately 130 countries. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).
Thomson scientific information solutions can be found at www.scientific.thomson.com and include, ISI Web of Knowledge--facilitating discovery by offering seamless navigation to high-quality, multidisciplinary journal (Web of Science), patent (Derwent World Patents Index), and Web content, evaluation tools, and bibliographic management products (EndNote); Thomson Pharma--an integrated information solution for the pharmaceutical and biotechnology markets; Delphion--providing access to full-text patent documents from the world's leading patent authorities; Techstreet-- offering a wide variety of engineering codes and standards; BIOSIS Previews--the world's most comprehensive reference database for life science research; and Information Holdings Inc.--a leading provider of intellectual property and regulatory information products and services for professional end users in corporate and legal markets.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.